Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COPD-ST2OP anti-ST2 trial in COPD
2018-000919-24Phase 2Unknown
- Sponsor
- University of Leicester
- Start
- Jun 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in chronic obstructive pulmonary disease (COPD) comparing MSTT1041A (anti-ST2) with Placebo (2 arms). Primary endpoint: Frequency of moderate to severe COPD exacerbations. Status: unknown.
02
Drugs
astegolimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2018-000919-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000919-24.